JP2002511868A - 増殖性硝子体網膜症を治療するためのカルシウム遮断薬 - Google Patents

増殖性硝子体網膜症を治療するためのカルシウム遮断薬

Info

Publication number
JP2002511868A
JP2002511868A JP50558099A JP50558099A JP2002511868A JP 2002511868 A JP2002511868 A JP 2002511868A JP 50558099 A JP50558099 A JP 50558099A JP 50558099 A JP50558099 A JP 50558099A JP 2002511868 A JP2002511868 A JP 2002511868A
Authority
JP
Japan
Prior art keywords
compound
glutamate
patient
compounds
proliferative vitreoretinopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50558099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002511868A5 (cg-RX-API-DMAC10.html
Inventor
ドレイヤー,エバン・ビー
Original Assignee
アラーガン・セイルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラーガン・セイルズ・インコーポレイテッド filed Critical アラーガン・セイルズ・インコーポレイテッド
Publication of JP2002511868A publication Critical patent/JP2002511868A/ja
Publication of JP2002511868A5 publication Critical patent/JP2002511868A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP50558099A 1997-06-30 1998-06-15 増殖性硝子体網膜症を治療するためのカルシウム遮断薬 Ceased JP2002511868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5196297P 1997-06-30 1997-06-30
US60/051,962 1997-06-30
PCT/US1998/012414 WO1999000129A1 (en) 1997-06-30 1998-06-15 Calcium blockers to treat proliferative vitreoretinopathy

Publications (2)

Publication Number Publication Date
JP2002511868A true JP2002511868A (ja) 2002-04-16
JP2002511868A5 JP2002511868A5 (cg-RX-API-DMAC10.html) 2005-12-22

Family

ID=21974492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50558099A Ceased JP2002511868A (ja) 1997-06-30 1998-06-15 増殖性硝子体網膜症を治療するためのカルシウム遮断薬

Country Status (6)

Country Link
US (4) US6380261B1 (cg-RX-API-DMAC10.html)
EP (1) EP0994709A4 (cg-RX-API-DMAC10.html)
JP (1) JP2002511868A (cg-RX-API-DMAC10.html)
AU (1) AU727080B2 (cg-RX-API-DMAC10.html)
CA (1) CA2295098A1 (cg-RX-API-DMAC10.html)
WO (1) WO1999000129A1 (cg-RX-API-DMAC10.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
AU5251999A (en) * 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
AU761824B2 (en) * 1998-10-27 2003-06-12 Alcon Laboratories, Inc. Treatment of disorders of the outer retina
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
WO2000038703A1 (en) * 1998-12-24 2000-07-06 R-Tech Ueno, Ltd. Agent for treating visual cell function disorder
JP2002182418A (ja) * 2000-12-11 2002-06-26 Konica Corp 画像形成方法、画像形成装置
FR2822706A1 (fr) * 2001-03-29 2002-10-04 Univ Pasteur Utilisation de composes organiques antagonistes de recepteurs pour le traitement de la degenerescence retinienne
US8557855B2 (en) * 2002-07-03 2013-10-15 Allergan, Inc. Methods of using ryanodine antagonists in treating neural injury
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2005097121A1 (en) * 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
US20050277139A1 (en) * 2004-04-26 2005-12-15 Itzhak Bentwich Methods and apparatus for the detection and validation of microRNAs
US7122128B2 (en) * 2004-04-29 2006-10-17 General Electric Company Phosphors containing borate of terbium, alkaline-earth, and Group-3 metals, and light sources incorporating the same
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
JP2008507588A (ja) * 2004-07-26 2008-03-13 アラーガン、インコーポレイテッド 眼の病態を処置する方法
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
NZ716349A (en) 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
JP2017515800A (ja) 2014-04-08 2017-06-15 ザ・メソジスト・ホスピタル iNOS阻害組成物および乳がん治療薬としてのその使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US4755388A (en) * 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
AU4807790A (en) * 1988-12-05 1990-06-26 Houston Biotechnology Incorporated Therapeutic use of calcium entry blockers in retinal or optic nerve dysfunction
ZA906583B (en) * 1989-08-21 1991-09-25 Beth Israel Hospital Method and composition for the treatment of cutaneous,ocular,and mucosal hypersensitivity,inflammatory,and hyperproliferative conditions using topical preparations of nifedipine
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5602156A (en) * 1993-09-17 1997-02-11 The United States Of America As Represented By The Department Of Health And Human Services Method for inhibiting metalloproteinase expression
US5424321A (en) * 1993-12-08 1995-06-13 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
FR2717080B1 (fr) * 1994-03-09 1996-12-13 Synthelabo Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
US5431907A (en) * 1994-08-03 1995-07-11 Abelson; Mark B. Treatment of vascular disorders of the posterior segment of the eye by topical administration of calcium channel blocking agents
US5623051A (en) * 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
FR2738567B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de alpha-phenylpiperidine-1-propanol, leur preparation et leur application en therapeutique
TR199800407T1 (xx) 1995-09-08 1998-05-21 Synthelabo 4-(Sikloalkil) piperidin ve t�revleri, haz�rlan��lar�, tedavi ama�l� kullan�mlar�.
FR2738568B1 (fr) 1995-09-08 1997-10-17 Synthelabo Derives de 4-(cycloalkyl)piperidines et 4-(cycloalkylalkyl) piperidines, leur preparation et leur application en therapeutique
US6380261B1 (en) 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
AU761824B2 (en) 1998-10-27 2003-06-12 Alcon Laboratories, Inc. Treatment of disorders of the outer retina
US6482854B1 (en) * 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment

Also Published As

Publication number Publication date
US20050192322A1 (en) 2005-09-01
EP0994709A1 (en) 2000-04-26
EP0994709A4 (en) 2006-02-01
US6380261B1 (en) 2002-04-30
US6573280B2 (en) 2003-06-03
US8101635B2 (en) 2012-01-24
AU727080B2 (en) 2000-11-30
US20030199551A1 (en) 2003-10-23
CA2295098A1 (en) 1999-01-07
AU7967298A (en) 1999-01-19
WO1999000129A1 (en) 1999-01-07
US7230032B2 (en) 2007-06-12
US20030060510A1 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
AU683634B2 (en) Glaucoma treatment
Schuman et al. Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys
Fraunfelder et al. Ocular toxicity of antineoplastic agents
US6573280B2 (en) Calcium blockers to treat proliferative vitreoretinopathy
KR100405285B1 (ko) 합성 티로이드 호르몬을 포함하는 약제 조성물
US20250134881A1 (en) Treatment of ocular inflammatory diseases using laquinimod
EP1397138B1 (de) WIRKSTOFF-KOMBINATION (z.B. Galanthamin oder Desoxypeganin mit Acamprosat oder Memantin) ZUR MEDIKAMENTÖSEN SUCHT- ODER RAUSCHMITTELTHERAPIE
JPH0320219A (ja) 眼内圧降下に有用な選択性α―アドレナリン作働剤および拮抗剤の組み合わせ
Gregory Timolol reduces IOP in normal NZW rabbits during the dark only.
US5212168A (en) Method of and solution for treating glaucoma
US7247623B2 (en) Method of treating dry eye disease with non-drying antihistamines
JPH08501313A (ja) ニューロトロフィンを使用する鎮痛作用生起方法
Goetting et al. Systemic atropine administration during cardiac arrest does not cause fixed and dilated pupils
JP2001500113A (ja) 精神遅滞を処置する方法
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
JP2002530342A (ja) 眼血管新生疾患の処置のためのスタウロスポリン誘導体の使用
US6489356B2 (en) Method for treating pain in humans
US5153205A (en) Method to reduce introacular pressure without causing miosis
WO2003063879A1 (en) Remedies for glaucoma comprising bunazosin and prostaglandins
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
Lacheretz et al. Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension
JP2001523724A (ja) 運動ニューロン病および脱髄病を治療するためのシチコリン
US20030064932A1 (en) Methods of treatment comprising administration of Substance P
US20050009884A1 (en) Calcium blockers to treat proliferative retinal diseases
US3644647A (en) Treatment of glaucoma employing 5-(3-methylaminopropyl - 5h - dibenzo(a b) cycloheptene

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090209

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090519